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Oleoyl-estrone (OE) is an adipose-derived signal that de-
creases energy intake and body lipid, maintaining energy ex-
penditure and glycemic homeostasis. Glucocorticoids protect
body lipid and the metabolic status quo. We studied the com-
bined effects of OE and corticosterone in adrenalectomized
female rats: dailyOEgavages (0 or 10 nmol/g) and slow-release
corticosterone pellets at four doses (0, 0.5, 1.7, and 4.8 mg/d).
Intact and sham-operated controls were also included. After
8 d, body composition and plasma metabolites and hormones
were measured. OE induced a massive lipid mobilization (in
parallel with decreased food intake and maintained energy
expenditure). Corticosterone increased fat deposition and in-
hibited the OE-elicited mobilization of body energy, even at
the lowest dose. OE enhanced the corticosterone-induced rise
in plasma triacylglycerols, and corticosterone blocked the
OE-induced decrease in leptin. High corticosterone and OE
increased insulin resistance beyond the effects of corticoste-
rone alone. The presence of corticosterone dramatically af-
fectedOE effects, reversing its decrease of body energy (lipid)
content, with little or no change on food intake or energy
expenditure. The maintenance of glycemia and increasing in-
sulin in parallel to the dose of corticosterone indicate a de-
crease in insulin sensitivity, which is enhanced by OE. The
reversal of OE effects on lipid handling, insulin resistance,
can be the consequence of a corticosterone-induced OE resis-
tance. Nevertheless, OE effects on cholesterol were largely
unaffected. In conclusion, corticosterone administration ef-
fectively blocked OE effects on body lipid and energy balance
as well as insulin sensitivity and glycemia. (Endocrinology
148: 4056–4063, 2007)
OLEOYL-ESTRONE (OE) IS an adipose tissue-derivedhormonal signal that elicits the decrease of body fat
stores (1). This is accomplished by decreasing white adipose
tissuemass (2) through apoptosis (3) andmassive loss of lipid
(4), accompanied by a decrease in food intake and the main-
tenance of energy expenditure (2). The pharmacological dos-
ing of OE results in the loss of fat in genetic (5, 6) or dietary
(7) models of obesity, even when high-lipid diets were used
(8, 9). OE also decreases insulin resistance and improves
hyperlipidemia, especially by lowering the levels of choles-
terol (2, 6, 9–12).
The effects of an iv infusion of OE on the energy balance
of adrenalectomized rats are even more marked, causing the
practical exhaustion of the animal’s reserves (13). In addition,
the administration of OE induces a transient rise in the levels
of ACTH and corticosterone in rats (14), which are not cor-
related with the limited changes that OE induces on the
hypothalamic nuclei content of CRH (15).
Glucocorticoids are widely considered amain factor in the
development of the metabolic syndrome (16) because they
induce insulin resistance (17), increase the hepatic glucose
output (18), and increase blood lipids (19). Stimulation of the
hypothalamus-pituitary-adrenal axis often results in white
adipose tissue proliferation (20), increases in proinflamma-
tory cytokine production (21), and a derangement of the
carbohydrate-lipid energy homeostasis maintained by insu-
lin (22). The opposite actions of glucocorticoids and OE on
energy substrate handling andmetabolic control of glycemia
and lipidemia and the stimulation of glucocorticoid produc-
tion by OE hint at glucocorticoids playing a retentive or
inhibitory role on OE action, similar to that of the glucocor-
ticoid-induced insulin resistance (17), affecting the expres-
sion and regulation of the insulin signal transduction cascade
(23) as well as indirect actions such as modulation of glucose
and fatty acid availability, resulting in altered responses to
glucose (24). Glucocorticoids also decrease the metabolic re-
sponses to leptin, an effect that has been described as resis-
tance to leptin (25). In general, glucocorticoids minimize the
effects of agents that tend to modify the metabolic status quo
by decreasing the extent of change and recovering the mod-
ified parameters to their preset homeostatic condition (26). In
this context, it can be expected that physiological glucocor-
ticoid action will tend to thwart the deep changes that OE
induces on the energy and lipid economy.
Because OE has the potential to become an antiobesity
drug, the establishment of a possible OE resistance elicited
by glucocorticoids is of critical importance in its pharmaco-
logical development and eventual deployment. In the
present study, we analyzed the effects of different doses of
corticosterone on the lipid-mobilizing effects of OE on a
model of adrenalectomized rats.
Materials and Methods
Animals and experimental setup
Female Wistar rats (Harlan-Interfauna, Sant Feliu de Codines, Spain)
weighing 225–245 g were used. After acclimation to the animal house,
part of the animals were adrenalectomized or sham operated under
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isoflurane anesthesia (d5) and left to recover for 5 d. Bilateral removal
of the adrenals was achieved through two small dorsolateral skin inci-
sions; the glandswere pulled out by holding the periadrenal fat and then
excised. Sham-operated animals were handled in the same way as adre-
nalectomized animals except that the adrenals were not cut and
removed.
All animals had free access to pellet food (maintenance chow; Panlab,
Barcelona Spain) and tap water; adrenalectomized rats had the water
substituted by a saline solution (9 g/liter NaCl). The rats were kept in
individual cages in a light- (12 h cycle), temperature- (21–22 C), and
humidity- (74–77%) controlled and quiet environment.
In addition to sham-operated controls, a group of intact rats (i.e. not
subjected to surgery or pellet implants)were used as control of the effects
of surgery. The rats received a daily gavage (from d 0 to 8) of 0.2 ml
sunflower oil, alone or containing OE (OED, Barcelona, Spain) at a dose
of 10 nmol/g of body weight per day. Corticosterone dosing was
achieved by implanting sc in the back the same day surgery (sham or
adrenalectomy, d 5) was performed, with slow-releasing, cholesterol-
free corticosterone pellets (Innovative Research of America, Sarasota,
FL), which liberated the hormone continuously for 21 d. Pellets of 0
(placebo), 10, 35, and 100 mg corticosterone were used, yielding daily
doses of 0, 0.5, 1.7, and 4.8 mg/d.
The groups included in the present study were: 1) intact rats im-
planted with placebo pellets (both controls and OE); 2) sham-operated
rats implanted with placebo pellets (both controls and OE); 3) adrena-
lectomized rats implanted with placebo pellets (both controls and OE)
(all placebo-treated rats thus receiving 0 mg of corticosterone); 4) adre-
nalectomized rats implanted with 10-mg pellets of corticosterone (both
controls and OE) (corresponding to a daily dose of 0.5 mg corticoste-
rone); 5) adrenalectomized rats implanted with 35-mg pellets of corti-
costerone (both controls and OE) (corresponding to a daily dose of 1.7
mg corticosterone); and 6) adrenalectomized rats implanted with
100-mg pellets of corticosterone (both controls and OE) (corresponding
to a daily dose of 4.8 mg corticosterone). In all cases the daily weight and
food consumption were recorded.
The experimental setup and procedures were approved by the Ethics
Committee of the University of Barcelona. All animal handling proce-
dures were carried out following the guidelines established by the Eu-
ropean Union and the Spanish and Catalan governments.
Sample preparation and analytical procedures
On d 8, the rats were quietly taken out of their cages and killed by
decapitation in less than 30 sec within 1–2 h after the beginning of the
light cycle (0800 h). Blood was recovered, left to clot, and centrifuged to
obtain serum, which was kept frozen until processed. The rats were
dissected, and the stomach and intestinal contents were removed; the
carcass and organs were sealed in polyethylene bags, autoclaved, and
thoroughly homogenized (2). Net body weight (i.e. crude wet weight
minus stomach and intestinal content) was used for body composition
analysis and calculations.
The rat paste energy content wasmeasured using a bomb calorimeter
(C-7000; Ika, Heitersheim, Germany). The paste was also used for the
estimation of lipid (27), water (differential weighing after 24 h in an oven
at 90 C), and protein, through Kjeldahl nitrogen analysis (Tecator; Foss,
Hillerød, Denmark) and the use of a rat-specific N to protein factor (28).
The energy content of the rats at the beginning of the experiment was
estimated by applying, to their surgery-day weights, the energy density
found in control (oil gavage) intact rats.
Energy intake was estimated from the food consumed, which con-
tained a metabolizable energy of 13.3 kJ/g. Energy accrual was the
difference between estimatedwhole-body energy content on the surgery
day and the energy measured (bomb calorimeter) on d 8. Mean energy
expenditure was estimated as the difference between energy intake and
net energy accrual.
Blood serum was used for the measurement of glucose (kit glucose
PAP CP; Horiba ABX, Montpellier, France), nonesterified fatty acids
(NEFAs) kit (Wako Chemicals, Neuss, Germany), total triacylglycerols
(kit 11528; Biosystems, Barcelona, Spain), total and high-density lipopro-
tein (HDL)-cholesterol (cholesterol reagent easy; Menarini, Firenze, It-
aly), insulin (SRI-13K; Linco, St. Charles, MO), leptin (RL-83K; Linco),
and adiponectin (MADP-60HK; Linco). Serum corticosterone levels
weremeasured by radioimmunoanalysis after acetone deproteinization,
(29) using a specific antibody (AB1297; Chemicon International, Te-
mecula, CA).
Statistical analysis
Statistical comparisons between groups were established by one-,
two-, or three-way ANOVAs and the post hoc Bonferroni test, using the
programs Statgraphics plus 5.1 (Manugistics, Rockville, MD) and Prism
4 (GraphPad, San Diego, CA).
Results
Corticosterone response to treatments
The serum levels of corticosterone in the different groups
are presented in Fig. 1. The levels were maximal in the sham-
operated rats and also in intact rats, showing the stress as-
sociated with manipulation and killing. Adrenalectomy in-
duced significant effects (P 0.0133), whereas surgery alone
and OE did not affect serum corticosterone significantly.
Adrenalectomized rats showed negligible basal corticoste-
rone concentrations that, as expected, increased with the
dose of corticosterone (P  0.0000). Substitutive corticoste-
rone administration resulted in levels within the span of a
circadian cycle (30). Again, OE did not affect the levels of
corticosterone nor was there a significant interaction be-
tween both steroids’ effects.
Body composition
Table 1 shows the body weight and composition changes
of intact, sham-operated, and adrenalectomized rats after
treatment with OE. Treatments did not result in statistically
significant differences of final body weights between the
groups. However, OE induced a significant difference in
body weight change during the 8-d treatment.
Body total energy content (bomb calorimeter) was unal-
tered by surgery: the difference in energy of control and OE
rats was similar for intact and sham-operated rats but in-
creased by the additive effects of adrenalectomy and OE.
OE-induced body lipid content differences in intact and
sham-operated rats was in the range of 5–6 g, which rose to
9 g in adrenalectomized rats. Surgery caused an increase of
FIG. 1. Serum corticosterone of intact, sham-operated, and adrena-
lectomized (ADX) rats subjected to OE and corticosterone treatments.
The columns represent the mean  SEM of six different animals.
White, Controls; black, OE-treated rats.
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5–6 g (sham-operated vs. intact controls) that turned in net
loss of approximately 10 g in adrenalectomized animals.
There were no significant changes in total body protein
caused by surgery, adrenalectomy, or OE treatment. Total
body water, on the contrary, was not affected by OE but
decreased because of surgery and increased as the conse-
quence of loss of adrenal gland function. However, the per-
centage of water in the rat was unaffected by surgery and
increased both with adrenalectomy and OE.
Figure 2 presents the effects of varying doses of cortico-
sterone combined with OE on body weight, lipid, protein,
and water. Corticosterone decreased body weight (P 
0.0033) only at the 4.8 mg/d dose; when combined with OE,
the body weight vs. corticosterone dose curve was bell
shaped, with lower values at 0 and 4.8 mg/d. OE induced
significant losses of lipid (P  0.0195), although this effect
waned out in the presence of additional corticosterone, re-
sulting in indistinguishable patterns for controls and OE rats
already from doses as low as 0.5 mg/d. No changes attrib-
utable to OE were observed in the whole-body protein pool
of intact, sham, or adrenalectomized rats, but OE decreased
the protein content in rats treated with corticosterone (P 
0.0029). The pattern of change of total body water in rats
treated with corticosterone (P  0.0019) followed that de-
scribed for body weight change because changes in water
and lipid largely justified the modifications of body weight
observed.
Table 2 presents the energy balance of intact, sham-oper-
ated, and adrenalectomized rats treated with OE. Energy
intake was decreased by surgery, adrenalectomy, and OE.
The latter induced decreases of 13–17% in food intake with
respect to their corresponding controls. Surgery reduced
food intake by 16% and adrenalectomy by almost one third.
The effects of surgery, loss of adrenal gland function, andOE
treatment were practically additive, with adrenalectomized
and OE-treated rats eating about 60% of intact controls. En-
ergy accrual was unaffected by surgery but decreased with
adrenalectomy and OE treatment again in additive fashion.
Energy expenditure decreased by surgery and adrenalec-
tomy and was in the limit of significance for OE treatment.
The effects of corticosterone and OE on the energy balance
components of adrenalectomized rats are depicted in Fig. 3.
Corticosterone induced a slow (albeit not significant) rise in
energy intake, but OE-treated rats always showed lower
values (P  0.0062). Energy accrual in OE-treated rats in-
creased from the marked negative values of placebo-adre-
nalectomized rats to lower, albeit negative, values at the
highest doses (OE, P  0.0000; corticosterone, P  0.0017).
Energy expenditure did not change significantly with in-
creasing corticosterone.
Metabolic parameters
Plasma glucose (Table 3) was unaffected by surgery, ad-
renalectomy, or OE treatment. Triacylglycerols were not af-
fected by OE but decreased in the absence of the adrenal
glands because surgery alone resulted in no effects. Choles-
terol behaved in a differentway because here neither surgery
nor the absence of adrenal glands affected its levels, which
were halved by OE. The HDL-cholesterol fraction (most of
the cholesterol in the rat) followed a similar pattern, but in
this case adrenalectomy by itself also reduced (effect not
additive with that of OE) HDL-cholesterol. Surgery in-
creased, but adrenalectomy and OE decreased the NEFAs
largely in an additive way.
Figure 4 presents the effects of corticosterone and OE on
plasma metabolites of adrenalectomized rats. Under the ex-
perimental conditions tested, corticosterone dose tended to
decrease glycemia (P  0.0407). Adrenalectomized OE
groups maintained higher glucose levels than their controls
(P 0.0015), irrespective of corticosterone dosing; this effect
contrastswith the glucose-lowering effect ofOEon intact and
sham-operated rats.
Triacylglycerols were significantly increased in OE-
treated rats (P  0.0070), compared with those receiving
corticosterone alone; the effect was not observed in placebo-
treated adrenalectomized rats, which suggests its depen-
dence on corticosterone although not dose dependent (P 
0.0088). The levels of NEFAs were affected by the dose of
corticosterone (P  0.0294) but not OE treatment.
The marked hypocholesterolemic effect of OE was main-
tained, even in the presence of increasing doses of cortico-
TABLE 1. Body weight and composition changes of intact, sham-operated, and adrenalectomized rats treated 8 d with oral OE
Parameter Units Intact Intact-OE Sham Sham-OE Adx Adx-OE
P
Surgery Adx OE
Body weight Surgery day g 236  3
Initial g 243  3 234  8 234  3 NS NS
Final g 245  4 237  4 236  11 231  11 235  3 221  4 NS NS NS
Change in 8 d g 6.0  1.5 7.2  2.3 0.6  1.1 2.8  1.1 3.8  1.7 8.4  4.6 NS NS 0.0011
Body energy
(final)
Content MJ 2.51  0.12 2.34  0.07 2.49  0.15 2.29  0.14 1.88  0.05 1.53  0.05 NS 0.0000 0.0058
Density kJ/g 10.4  0.4 10.1  0.2 11.2  0.4 10.8  0.3 8.3  0.2 7.3  0.1 0.0145 0.0000 0.0198
Body lipid
(final)
Content g 31.0  2.0 26.3  1.3 36.6  3.8 30.6  2.7 21.0  1.5 11.8  1.4 0.0282 0.0000 0.0001
Density % 12.9  0.8 11.4  0.5 16.5  1.3 14.0  0.9 9.2  0.6 5.6  0.5 0.0003 0.0000 0.0004
Body protein
(final)
Content g 43.2  1.6 40.2  0.6 39.1  0.6 39.5  1.4 41.5  0.8 39.0  0.9 NS NS NS
Density % 17.9  0.5 17.4  0.2 16.6  0.6 18.1  0.4 18.2  0.2 18.5  0.2 NS 0.0312 NS
Body water
(final)
Content g 149.2  3.0 146.2  2.6 138.3  3.6 138.2  6.8 147.9  1.4 144.5  2.7 0.0135 0.0334 NS
Density % 61.9  0.8 63.3  0.7 60.2  1.6 63.4  1.0 64.9  0.6 68.7  1.2 NS 0.0001 0.0029
The values are the mean  SEM of six different animals. The P column reflects the statistical significance of the differences between groups
(three-way ANOVA); NS, P  0.05; Adx, Adrenalectomy.
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sterone; at the highest doses of the latter, cholesterol levels
tended to increase in parallel in both groups. The HDL-
cholesterol fraction of rats receiving corticosterone increased
in parallel to the dose of this hormone; however, OE treat-
ment maintained lower levels of HDL-cholesterol (P 
0.0000) that tended to further decrease with higher doses of
corticosterone.
Insulin (Table 3) was not significantly affected by surgery,
but decreased with the loss of the adrenal function and fur-
ther decreased by OE treatment. Adiponectin followed
roughly the same pattern, with additive effects of adrenal-
ectomy and OE treatment. OE markedly lowered leptin lev-
els (in additive fashion) with adrenalectomy, down to un-
detectable levels in placebo adrenalectomized rats.
Figure 5 presents the plasma levels of insulin, leptin, and
adiponectin of adrenalectomized rats treated with OE and
corticosterone. Insulin, leptin, and adiponectin increased
along with corticosterone (P  0.0003, P  0.0011, and P 
0.0032, respectively). In the presence of corticosterone, the
OE-induced decrease in insulin levels was reversed at the
1.7-mg/d dose. OE decreased leptin (P  0.0033) and adi-
ponectin (P  0.0000). The combined treatment of OE and
corticosterone resulted in a dramatic recovery of the nil leptin
levels of placebo rats, up to the values of their 4.8 mg/d
corticosterone controls.
Discussion
Oral OE effects on energy balance are enhanced in adre-
nalectomized rats, probably because of the lack of inhibition
exerted by the adrenal gland-derived glucocorticoids. This is
further stressed by the powerful inhibitory effect of cortico-
sterone pellets on the lipid mobilization elicited by OE. The
presence of glucocorticoids, even at a low dose emulating
basal glucocorticoid production (31), results in the practical
elimination of the inhibition of leptin synthesis and insulin
decrease induced by OE. It also induced marked increases of
serum triacylglycerols and NEFAs and, especially, a dra-
matic decrease of the mobilization of lipids elicited by OE.
The implantation of corticosterone pellets in adrenalecto-
mized rats could not be fully compared with the function of
normal adrenal glands because the secretion of dehydroepi-
androsterone, an antiglucocorticoid (32), or those of miner-
alocorticoids, androgens, and estrogens as well as medullar
catecholamineswas notmimicked in our experimental setup.
However, the pellet implant model has been widely and
successfully used in studies in which a constant release of
glucocorticoid was needed (31). The model was checked and
found that circulating corticosterone was correlated with the
pellet dose; the levels were lower than those of intact and
sham-operated controls because the absence of adrenal
glands prevents the spiked response to stress observed in
intact and sham-operated rats. The serum corticosterone of
adrenalectomized rats treated with hormone pellets agree
TABLE 2. Energy balance of intact, sham-operated, and adrenalectomized rats treated 8 d with oral OE
Parameter Units Intact Intact-OE Sham Sham-OE Adx Adx-OE
P
Surgery Adx OE
Energy intake W 2.62  0.13 2.17  0.08 2.20  0.10 1.88  0.11 1.82  0.06 1.59  0.12 0.0016 0.0023 0.0006
Energy accrual W 0.10  0.09 0.04  0.08 0.11  0.06 0.03  0.06 0.49  0.03 0.70  0.06 NS 0.0000 0.0045
Energy expenditure
(calculated)
W 2.52  0.11 2.22  0.14 2.05  0.06 1.80  0.06 2.30  0.07 2.32  0.11 0.0002 0.0011 0.0473
The values are the mean  SEM of six different animals. The P column reflects the statistical significance of the differences between groups
(three-way ANOVA); NS, P  0.05; Adx, adrenalectomy.
FIG. 2. Body weight and composition of adrenalectomized rats
treated 8 d with oral OE receiving different doses of corticosterone.
The symbols represent the mean  SEM of six different animals.
Controls, Open circles and continuous line; OE, black circles and
dashed lines. Significant differences between same-dose groups (P 
0.05; Bonferroni post hoc test) are marked with asterisks. Initial body
weights of the experimental groups (mean  SEM) were: d 5: 236 
2 g; d 0: dose 0mg/d: 234 3 g; dose 0.5mg/d: 233 2 g; dose 1.7mg/d:
234  3 g; dose 4.8 mg/d: 227  3 g.
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with previously described levels within the normal circadi-
an-cycle span, with the 0.5 mg/d dose akin to the nadir and
the 4.8 mg/d dose close to the maximal daily values (30, 31).
To minimize (or control) the variables due to surgical
manipulation, we included two sets of controls in our study:
controls of surgery (i.e. sham-operated vs. intact rats) and
adrenalectomy (i.e. adrenalectomized vs. sham-operated), to
determine the actual effects of OE on adrenalectomized an-
imals discounting (as much as possible) the influence of
surgery and stress. Surgery and adrenalectomy effects in-
cluded a 13-d span (i.e. from d5 to d 8), whereas OE effects
included only 8 (i.e. from d 0 to 8). Surgery and the stress it
carries affected (independently of the other treatments) body
lipids and NEFAs.
Corticosterone affects body weight following a bell-
shapedweight vs. dose curve as described (31). However, the
pattern we found was less marked, probably because of a
different range of doses used, the age of the rats, and the
duration of the experiment (31). Body weight did not follow
the lipid content changes in corticosterone-treated rats; cor-
ticosterone increased fat deposition, in agreement with pre-
vious reports (33). On the other hand, OE-induced decreases
in body weight were mainly the consequence of massive
losses of body lipid, with less marked changes in water and
protein (2). The combination of OE and corticosterone en-
hanced the effects of the two treatments on bodyweight,with
maximal losses both at low and high corticosterone doses.
This pattern closely followed that of body water change.
Because the proportion of body water was severalfold larger
than that of lipid, the changes in lipid provoked by OE and
corticosterone were translated into less marked body weight
changes than the alterations in body water. The mutual in-
fluence on body water/weight by large doses of corticoste-
rone and OE were not paralleled by changes in lipid or other
parameters, suggesting that the interrelations between OE
and glucocorticoids are broader than expected.
The surprising decrease of adiponectin in both adrenalec-
tomized and OE-treated rats suggests that it may be directly
or indirectly modulated by OE and glucocorticoids. The adi-
ponectin decrease, in parallel with decreased insulin resis-
tance (i.e. lower insulin and maintained glycemia), contrasts
with the known parallelism of adiponectin and insulin sen-
sitivity (34, 35) and decreased adipose mass and adiponectin
secretion (36). Despite corticosterone restoring adiponectin
levels, the OE-induced decrease of adiponectin (37) seems to
override, in our experimental setup, the conditions favoring
increased adiponectin.
The effects of oral OE on the energy levels of adrenalec-
tomized rats are less dramatic than those observed previ-
FIG. 3. Energy balance components of adrenalectomized rats treated
8 d with oral OE receiving different doses of corticosterone. The
symbols represent the mean SEM of six different animals. Controls,
Open circles and continuous line; OE, black circles and dashed lines.
The graphs show the effects on energy balance (in watts) along the
whole span of the experiment (from d 5 to d 8). Significant differ-
ences between same-dose groups (P  0.05; Bonferroni post hoc test)
are marked with asterisks.
TABLE 3. Serum levels of metabolites, cytokines, and hormones of intact, sham-operated, and adrenalectomized rats treated 8 d with
oral OE
Parameter Units Intact Intact-OE Sham Sham-OE Adx Adx-OE
P
Surgery Adx OE
Glucose mM 8.21  0.29 6.70  0.20 7.39  0.23 7.08  0.19 7.34  0.11 8.10  0.22 NS NS NS
Triacylglycerols mM 1.62  0.2 1.47  0.3 1.71  0.1 1.58  0.1 0.67  0.06 0.51  0.07 NS 0.0000 NS
NEFAs mM 0.40  0.03 0.36  0.03 0.53  0.04 0.40  0.03 0.33  0.05 0.21  0.01 0.0270 0.0000 0.0030
Cholesterol mM 0.69  0.03 0.35  0.06 0.64  0.10 0.39  0.01 0.59  0.03 0.30  0.03 NS NS 0.0000
HDL-cholesterol mM 0.65  0.07 0.14  0.02 0.63  0.12 0.22  0.11 0.40  0.04 0.24  0.03 NS 0.0344 0.0000
Insulin pM 292  21 210  21 204  41 157  24 161  19 100  22 NS 0.0272 0.0028
Leptin pM 169  20 88  13 206  22 151  19 118  50 Not detectable NS 0.0002 0.0006
Adiponectin nM 144  12 109  1 131  7 108  18 96  16 40  3 NS 0.0004 0.0010
The values are the mean  SEM of six different animals. The P column reflects the statistical significance of the differences between groups
(three-way ANOVA); NS, P  0.05; Adx, adrenalectomy.
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ously using iv OE (13). In the present study, we observed an
additive effect of adrenalectomy and OE on body energy
stores, which suggests that the mechanisms may not be co-
incident. Both processes affected negatively (and additively)
food intake and lipid mobilization; however, OE maintained
and adrenalectomy decreased energy expenditure. OE ef-
fects were centered on the active mobilization of white ad-
ipose tissue lipid and its oxidation elsewhere (38), i.e. main-
taining the circulating levels of triacylglycerols in addition to
glucose. On the other hand, the effects of adrenalectomy
relied more on diminished food intake and lower energy
consumption, in some way intending to protect the fat stores
from exhaustion: leptin (but also insulin and adiponectin)
levels decreased but not as much as in the OE-treated rats.
The marked hypocholesterolemic effects of OE (10, 12) were
not paralleled in adrenalectomy alone, suggesting a fairly
different handling of lipoproteins in both models.
The less marked effects of OE on sham-operated rats vs.
intact controlsmaybe also attributed to the higher circulating
levels of glucocorticoids that this stressed group can be as-
sumed to present (39). The presence of even low levels of
corticosterone dramatically affectedOEperformance,mostly
reversing its effects on body energy (lipid) content, with little
or no change on food intake or energy expenditure. Main-
tenance of plasma glucose but increasing insulin levels in
parallel to dose of corticosterone indicate a decrease in in-
sulin sensitivity, an effect more marked on OE-treated rats.
OE alone is known to increase the muscle ability to fed on
lipids and consequently using less glucose (10). In the present
setup, because the release of lipids from adipose tissue is
inhibited by glucocorticoids (i.e. there is no significant mo-
bilization of body lipids) glucose may be again a preferred
peripheral substrate; however, OE hampers its uptake (thus
maintaining high glycemia throughout) further than glu-
cocorticoids. It can be then speculated that glucocorticoid-
mediated increased hepatic glucose output (18), a critical part
of its induction of insulin resistance (40), may help fulfill this
relative energy deficit, but peripheral glucose uptake now
requires a higher insulin secretion. Thus, paradoxically, the
FIG. 4. Serum levels of metabolites of adrenalectomized rats treated
8 d with oral OE receiving different doses of corticosterone. The
symbols represent the mean SEM of six different animals. Controls,
Open circles and continuous line; OE, black circles and dashed lines.
In the cholesterol panel, total cholesterol: controls, open circles; OE,
black circles; HDL-cholesterol: controls, open squares; OE, black
squares. Significant differences between same-dose groups (P 0.05;
Bonferroni post hoc test) are marked with asterisks.
FIG. 5. Serum levels of insulin and cytokines of adrenalectomized
rats treated 8 d with oral OE receiving different doses of corticoste-
rone. The symbols represent the mean SEM of six different animals.
Controls, Open circles and continuous line; OE, black circles and
dashed lines. Significant differences between same-dose groups (P 
0.05; Bonferroni post hoc test) are marked with asterisks.
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insulin-sensitizing agent OE compounds the insulin resis-
tance induced by glucocorticoids.
The reversal of OE effects on substrate handling, insulin
resistance, and the loss of its ability to mobilize lipid can be
at least in part justified by the assumption that corticosterone
induces an OE resistance similar to that glucocorticoids in-
duce on insulin (17) and leptin (25). The parallel (but more
marked) breakup of the OE inhibition of leptin synthesis by
corticosterone agreeswith thatOE resistance hypothesis. The
inhibitory effect of corticosterone on OE influence on lipid
mobilization (e.g. higher maintenance of body lipid) and
disposal (e.g. increased triacylglycerol levels) runs parallel to
the increases in adiponectin and insulin resistance induced
by corticosterone on rats treated with OE.
Curiously, the effect of OE on cholesterol levels is largely
unaffected by this postulated OE resistance, probably be-
cause the effect of OE on cholesterol lies more on the mod-
ulation of the cholesterol ester fraction (12) than its effect on
total cholesterol; this is better seen in the different behavior
of HDL-cholesterol, despite HDL being in the rat the main
lipoprotein carrying this steroid (41). It may be speculated
that corticosterone also affects the ability of OE to mobilize
cholesterol esters, which would add to the postulated OE
resistance induced by glucocorticoid.
Adrenalectomized rats receiving 0.5 mg/d dose have
lower sustained circulating corticosterone levels, at the lower
end of a normal daily cycle (30), than intact or sham-operated
rats, even discounting the stress of handling and being killed.
However, OE deeply decreases body lipids and shows its
complete set of metabolic effects in animals with intact adre-
nals, which are blocked by the postulated OE resistance
induced by corticosterone at much lower levels. This may be
the consequence of other adrenal gland-secreted factors that
partly counteract the OE resistance of corticosterone. The
postulated secretion is not necessary for OE action because
the effects of OE on adrenalectomized rats are in fact en-
hanced by the lack of corticosteroids. It is much more prob-
able then that adrenal glands carry its own glucocorticoid
antagonist or counteracting hormone. Further study is
needed to determine the nature of this control system and its
possible modulation of both OE and corticosterone function.
Dehydroepiandrosterone, a known antiglucocorticoid agent
(32), insulin sensitizer (42), and hormone precursor (43), pro-
duction of which is limited in the rat’s adrenals (33), may
fulfill this role of modulator. Another possibility is the ad-
renal medulla-secreted catecholamines; adrenergic agents
activate lipolysis (44) and enhance OE action in a synergistic
way (45).
In conclusion, the effects of OE on body energy balance
and its metabolic gearing to the mobilization of lipid stores
are markedly controlled, and potentially stopped altogether,
by natural glucocorticoids. In the rat, corticosterone admin-
istration effectively blocked most of the metabolic actions of
OE. We postulate that most of these deep interactions of
corticosteroids with OE metabolic effects may be the conse-
quence of a global resistance comparable with those de-
scribed for leptin and, especially, insulin. As a consequence,
it is suggested that the eventual use of OE as antiobesity drug
should take into consideration the evident interference of
glucocorticoids (or stress) on its slimming action.
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